These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38531953)

  • 1. Prognosis and chemotherapy drug sensitivity in liver hepatocellular carcinoma through a disulfidptosis-related lncRNA signature.
    Chen C; Wang C; Li Y; Jiang S; Yu N; Zhou G
    Sci Rep; 2024 Mar; 14(1):7157. PubMed ID: 38531953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer.
    Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel disulfidptosis-related lncRNAs signature for predicting survival and immune response in hepatocellular carcinoma.
    Guo Z; Xie Y; Zhang L; Liu S; Jiang W
    Aging (Albany NY); 2024 Jan; 16(1):267-284. PubMed ID: 38180745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.
    Liu Y; Meng J; Ruan X; Wei F; Zhang F; Qin X
    Sci Rep; 2024 Jan; 14(1):746. PubMed ID: 38185671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine learning-based disulfidptosis-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity in hepatocellular carcinoma.
    Pu L; Sun Y; Pu C; Zhang X; Wang D; Liu X; Guo P; Wang B; Xue L; Sun P
    Sci Rep; 2024 Feb; 14(1):4354. PubMed ID: 38388539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constructed Risk Prognosis Model Associated with Disulfidptosis lncRNAs in HCC.
    Jia X; Wang Y; Yang Y; Fu Y; Liu Y
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
    Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
    Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a novel disulfidptosis-related lncRNAs signature in patients with HPV-negative oral squamous cell carcinoma.
    Yang F; Niu X; Zhou M; Li W
    Sci Rep; 2024 Jun; 14(1):14436. PubMed ID: 38910181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel disulfidptosis-related lncRNA signature for predicting prognosis and potential targeted therapy in hepatocellular carcinoma.
    Zhang H; Wang J; Yang M
    Medicine (Baltimore); 2024 Jan; 103(4):e36513. PubMed ID: 38277541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma.
    Xu L; Chen S; Li Q; Chen X; Xu Y; Zhou Y; Li J; Guo Z; Xing J; Chen D
    Cancer Cell Int; 2024 Jan; 24(1):30. PubMed ID: 38218909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disulfidptosis-Associated lncRNAs are Potential Biomarkers for Predicting Immune Response and Prognosis Within Individuals Diagnosed with Hepatocellular Carcinoma.
    Wei Q; Hou YC; Mao FF; Feng JK; Wang X; Cheng SQ
    Hepat Med; 2023; 15():249-264. PubMed ID: 38162389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Analysis of Disulfidptosis-Related LncRNAs in Molecular Classification, Immune Microenvironment Characterization and Prognosis of Gastric Cancer.
    Kang K; Li X; Peng Y; Zhou Y
    Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer.
    Xing F; Qin Y; Xu J; Wang W; Zhang B
    Mol Biotechnol; 2024 Sep; 66(9):2396-2414. PubMed ID: 37733182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disulfidptosis-related lncRNA signatures assess immune microenvironment and drug sensitivity in hepatocellular carcinoma.
    Xu K; Dai C; Yang J; Xu J; Xia C; Li J; Zhang C; Xu N; Wu T
    Comput Biol Med; 2024 Feb; 169():107930. PubMed ID: 38199215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cuproptosis-Related LncRNA Signature for Predicting Prognosis of Hepatocellular Carcinoma: A Comprehensive Analysis.
    Chen Q; Sun T; Wang G; Zhang M; Zhu Y; Shi X; Ding Z
    Dis Markers; 2022; 2022():3265212. PubMed ID: 36452343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
    Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
    Front Immunol; 2021; 12():719175. PubMed ID: 34603293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.